Search

The article discusses updated data as of 2024 which shows that adjuvant pembrolizumab (Keytruda) extended overall survival (OS) in patients with clear cell renal cell carcinoma (ccRCC) at medium or high risk of recurrence. It states that the therapy improved disease-free survival (DFS) and lowered distant and local disease recurrence. Also noted are the occurrences of immune-mediated adverse events (AE) and infusion reactions among patients.

The article focuses on a news release from AstraZeneca on the results of the phase three NIAGARA trial, which shows the effectiveness of the combination of durvalumab and chemotherapy in improving event-free survival and overall survival in patients with muscle-invasive bladder cancer. Topics discussed include the safety of durvalumab in the trial, and the selection of the participants.

The article discusses 2024 data which showed that blue light cystoscopy (BLC) is linked to improved outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) compared to white light cystoscopy (WLC). Topics covered include the comparatively lower recurrence risk and progression risk for patients following BLC, and the latter's improved overall survival. Also noted is improved tumor visualization's help in determining intravesical therapy use, such as Bacillus Calmette-Guerin (BCG).

The article focuses on the U.S. Food and Drug Administration (FDA) has approved Elahere for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients with prior systemic treatment. It reports that the approval was based on data from the confirmatory phase 3 MIRASOL trial, showing a reduction in death and cancer progression risk. Elahere, developed by ImmunoGen and acquired by AbbVie, targets folate receptor alpha.

The article focuses on the U.S. Food and Drug Administration's (FDA) approval of datopotamab deruxtecan (Dato-DXd) for treating non-small cell lung cancer (NSCLC), with an action date set for the fourth quarter of 2024. It reports that, if approved, it would be the first TROP2-directed antibody drug conjugate for NSCLC, a significant development considering lung cancer's high incidence and mortality rates.

The article reports on the approval by the U.S. Food and Drug Administration (FDA) of Onivyde (irinotecan liposome) as a first-line treatment of adult patients with metastatic pancreatic adenocarcinoma. The drug is indicated to be used with the chemotherapy regimen of oxaliplatin, fluorouracil and leucovorin (NALIRIFOX). Also cited is the comment of Professor Zev Wainberg of the UCLA GI Oncology program on the drug.

The article highlights Food and Drug Administration advisory meeting on March 15, 2024, to review Abecma's efficacy in earlier lines of treatment for relapsed or refractory multiple myeloma. Topics include the meeting's focus on overall survival data from the KarMMa-3 study, Abecma's performance in comparison to standard regimens, and its adverse event profile.